A Phase 2 interventional study of Phentolamine Mesylate Ophthalmic Solution 1% and Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo) in Open Angle Glaucoma and Ocular Hypertension, sponsored by Opus Genetics, Inc. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Opus Genetics, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.
Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 207th largest by enrollment of the 279 interventional ones that give a count, is one of 16 that started in 2019, is one of 76 in phase 2, and was the 215th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:
Tavo Biotherapeutics · Sites in United States
Ages 18+
Brett King · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 20–79 · Healthy volunteers
YS Life Science Co., Ltd. · Sites in United States, India
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
348 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 99 · Phase 3 58 · Phase 4 36
First in 1976; this study’s year is marked. 16 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 84 across the 279 interventional studies, 100 across the 57 observational. Of the 260 that completed or were terminated, 117 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
228 of 348 have an industry lead sponsor. The 10 most frequent:
Opus Genetics, Inc is the lead sponsor of 17 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Opus Genetics, Inc has 1 study filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
24 of the studies in Glaucoma, Open-Angle with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05695027Phase 3Columbia UniversityNicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study | 2027-08 |
| NCT07661329Phase 3YS Life Science Co., Ltd.A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension | 2027-11-01 |
| NCT05626426Stanford UniversityElectrical Stimulation for the Treatment of Optic Neuropathies | 2026-12 |
| NCT05626491Stanford UniversityElectrical Stimulation for the Treatment of Glaucoma | 2026-12 |
| NCT05506423Iantrek, Inc.Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes | 2026-12 |
Add all 24 to your calendar (.ics) → With an account.
Among the 348 studies in Glaucoma, Open-Angle with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of this study are:
Placebo-controlled double-masked, multiple dose Phase 2 study in 40 patients with IOP ≥ 22 and ≤30 mmHg, evaluating ocular and systemic safety and efficacy following administration of Phentolamine mesylate 1.0% QD at 8PM to 10PM in both eyes for 14 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 drop in each eye daily (QD) at or before bedtime (8pm to 10pm) for 14 days
Drug: Phentolamine Mesylate Ophthalmic Solution 1%
1 drop in each eye daily (QD) at or before bedtime (8pm to 10pm) for 14 days
Other: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Topical Sterile Ophthalmic Solution
Also known as: Nyxol®
Topical Sterile Ophthalmic Solution
Intraocular Pressure
change from Baseline in mean diurnal IOP in the study eye
Time frame: 15 days
Pupil Diameter
Change from Baseline Pupil Diameter (Photopic Conditions)
Time frame: 15 days
Distance Visual Acuity
Percentage of Subjects Achieving ≥1 line improvement in Distance Visual Acuity from Baseline measured at 4 meters (photopic conditions)
Time frame: 15 days
Conjunctival Hyperemia
Conjunctival Hyperemia Category
Time frame: 15 days
| Milestone | Nyxol Ophthalmic Solution 1% | Nyxol Ophthalmic Solution Vehicle |
|---|---|---|
| Started | 19 | 20 |
| Completed | 19 | 20 |
| Not completed | 0 | 0 |
change from Baseline in mean diurnal IOP in the study eye
| mmHg | Nyxol Ophthalmic Solution 1% | Nyxol Ophthalmic Solution Vehicle |
|---|---|---|
| Intraocular Pressure | -2.30 ± 2.986 | -2.18 ± 1.856 |
Change from Baseline Pupil Diameter (Photopic Conditions)
| mm | Nyxol Ophthalmic Solution 1% | Nyxol Ophthalmic Solution Vehicle |
|---|---|---|
| Day 8 (8AM) | -0.77 ± 0.538 | -0.07 ± 0.555 |
| Day 15 (8AM) | -0.77 ± 0.550 | -0.01 ± 0.580 |
Percentage of Subjects Achieving ≥1 line improvement in Distance Visual Acuity from Baseline measured at 4 meters (photopic conditions)
| Participants | Nyxol Ophthalmic Solution 1% | Nyxol Ophthalmic Solution Vehicle |
|---|---|---|
| Distance Visual Acuity | 12 | 4 |
Conjunctival Hyperemia Category
| Participants | Nyxol Ophthalmic Solution 1% | Nyxol Ophthalmic Solution Vehicle |
|---|---|---|
| None | 4 | 8 |
| Mild | 10 | 8 |
| Moderate | 3 | 4 |
| Severe | 2 | 0 |
Collected over 14 Days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nyxol Ophthalmic Solution 1% | 0/19 (0%) | 0/19 (0%) | 5/19 (26.3%) |
| Nyxol Ophthalmic Solution Vehicle | 0/20 (0%) | 0/20 (0%) | 1/20 (5%) |
| Event | Nyxol Ophthalmic Solution 1% | Nyxol Ophthalmic Solution Vehicle |
|---|---|---|
| Conjunctival HyperemiaEye disorders | 3/19 | 1/20 |
| Installation Site DiscomfortGeneral disorders | 3/19 | 0/20 |
| Eye PruritisEye disorders | 1/19 | 0/20 |
| Age, Continuous(years) | Nyxol Ophthalmic Solution 1% | Nyxol Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| Mean | 58.1 ± 13.23 | 63.2 ± 10.35 | 60.7 ± 11.97 |
| Sex: Female, Male(Participants) | Nyxol Ophthalmic Solution 1% | Nyxol Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| Female | 9 | 13 | 22 |
| Male | 10 | 7 | 17 |
| Race/Ethnicity, Customized(Participants) | Nyxol Ophthalmic Solution 1% | Nyxol Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| White | 11 | 14 | 25 |
| Non-White | 8 | 6 | 14 |
| Baseline Intraocular Pressure (Study Eye)(mmHg) | Nyxol Ophthalmic Solution 1% | Nyxol Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| Mean | 23.43 ± 1.675 | 24.38 ± 2.097 | 23.92 ± 1.939 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2019 to primary completion in Sep 2019, 3 months.
Results were first posted in Jul 2023, 3 years 10 months after primary completion.
Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 3 months is below that.
Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Phentolamine
Opus Genetics, Inc